Skip to main content
. 2023 Apr 3;11(4):1082. doi: 10.3390/biomedicines11041082

Figure 2.

Figure 2

cfDNA levels at diagnosis were evaluated regarding the tumor characteristics. Statistically significant comparison where indicated by “*”. (A): cfDNA ng per mL plasma across tumor histologies (p = 0.0201, Kruskal–Wallis test). (B): cfDNA ng per mL plasma correlated with tumor stage (I/II–IV: p = 0.0227, III–IV: p = 0.0303). (C): Metastatic patients (n = 17) had higher levels of cfDNA at diagnosis compared with nonmetastatic patients (n = 18, p = 0.0153, Mann–Whitney U test). (D): Patients who developed metastasis during treatment (n = 11) also had higher levels of cfDNA compared to those who did not (n = 19, p = 0.0264, Mann–Whitney U test).